Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018315 · ClinicalTrials.gov registry record · Phase 1
Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
A Phase 1 study, sponsored by Juan Pascual.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02018315 is a Phase 1 study that has completed, run by Juan Pascual. The registered enrollment target is 14 participants.
The verdict
NCT02018315, a Phase 1 study, has completed, sponsored by Juan Pascual.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if an alternative energy source will impact brain metabolism in a disorder characterized by glucose metabolism failure in the brain. The central hypothesis tested in this investigation is whether circumventing impaired glucose metabolism is feasible, safe and potentially promising by supplying anaplerotic precursors through metabolism of odd-carbon fatty acids that can enter the citric acid cycle (CAC) through alternative metabolic pathways.
Interventions
- DRUG Triheptanoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02018315
The ClinicalTrials.gov registry entry for NCT02018315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juan Pascual, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triheptanoin is the first listed.
NCT02018315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02018315 about?
NCT02018315 is a clinical study titled "Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)". The purpose of this trial is to determine if an alternative energy source will impact brain metabolism in a disorder characterized by glucose metabolism failure in the brain. The central hypothesis tested in this investigation is whether circumventing impaired glucose metabolism is feasible, safe a...
What is the current status of trial NCT02018315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-01. Estimated completion is 2014-03.
What interventions are being tested in trial NCT02018315?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT02018315?
This trial is sponsored by Juan Pascual, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.